Background: Despite the large body of work on local field potentials (LFPs), a measure of oscillatory activity in patients with Parkinson's disease (PD), the longitudinal evolution of LFPs is less explored., Objective: To determine LFP fluctuations collected in clinical settings in patients with PD and STN deep brain stimulation (DBS)., Methods: Twenty-two STN-DBS patients (age: 67.6 ± 8.3 years; 9 females; disease duration: 10.3 ± 4.5 years) completed bilateral LFP recordings over three visits in the OFF-stimulation setting. Peak and band power measures were calculated from each recording., Results: After bilateral LFP recordings, at least one peak was detected in 18 (81.8%), 20 (90.9%), and 22 (100%) patients at visit 1, 2, and 3, respectively. No significant differences were seen in primary peak amplitude (F = 2.91, p = 0.060) over time. Amplitude of the second largest peak (F = 5.49, p = 0.006) and low-beta (F = 6.89, p = 0.002), high-beta (F = 13.23, p < 0.001), and gamma (F = 12.71, p < 0.001) band power demonstrated a significant effect of time. Post hoc comparisons determined low-beta power (Visit 1-Visit 2: t = 3.59, p = 0.002; Visit 1-Visit 3: t = 2.61, p = 0.031), high-beta (Visit 1-Visit 2: t = 4.64, p < 0.001; Visit 1-Visit 3: t = 4.23, p < 0.001) and gamma band power (Visit 1-Visit 2: t = 4.65, p < 0.001; Visit 1-Visit 3: t = 4.00, p < 0.001) were significantly increased from visit 1 recordings to both follow-up visits., Conclusion: Our results provide substantial evidence that LFP can reliably be detected across multiple real-world clinical visits in patients with STN-DBS for PD. Moreover, it provides insights on the evolution of these LFPs., Competing Interests: Declaration of competing interest AF: Owns stock in Inbrain Pharma; consultancies from Abbvie, Abbott, Boston Scientific, Ceregate, Inbrain, Ipsen, Medtronic, Iota, and Syneos Health; advisory boards for Abbvie, Boston Scientific, Ceregate, Inbrain, Ipsen; honoraria from Abbvie, Abbott, American Academy of Neurology, Boston Scientific, Brainlab, Ipsen, Medtronic, Merz, Movement Disorders Society, Sunovion, Paladin Labs, UCB, Sunovion; royalties from Springer; grants from Abbvie, Boston Scientific, Dystonia Medical Research Foundation, University of Toronto, Michael J Fox Foundation, Medtronic, MSA coalition, Praxis, ES. HM: No conflicts to declare. GO: Honoraria from Medtronic, Boston Scientific, Abbott Japan LLC Otsuka Pharmaceutical, Co. Ltd., Sumitomo Pharma Co. Ltd., Eisai Co., Ltd., FP pharma, Takeda Pharmaceutical Company LTD., Kyowa Hakko Kirin Co. Ltd., and AbbVie, Inc.; grants from Grant from the Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C) (#21K12711s). NM: No conflicts to declare. TW: No conflicts to declare. YH: No conflicts to declare. AS: Employed by Medtronic. CS: Owns stock in Medtronic; employed by Medtronic. NM: Owns stock in Medtronic; employed by Medtronic., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)